News >

Emerging Agents Spur Optimism in Myeloma

Brandon Scalea
Published: Monday, May 06, 2019

Saurabh Chhabra, MD, MS

Saurabh Chhabra, MD, MS

The addition of elotuzumab (Empliciti) to the treatment arsenal for relapsed/refractory myeloma is arguably the biggest advance made in the space within the past year, according to Saurabh Chhabra, MD, MS. However, antibody-drug conjugates and CAR T-cell therapies are also making headway within the paradigm.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication